- Home
- CYH vs PLRX Comparison
CYH vs PLRX Comparison
Compare CYH & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYH | PLRX |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.2M | 93.3M |
| IPO Year | 1991 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CYH | PLRX |
|---|---|---|
| Price | $3.12 | $1.26 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 7 | 11 |
| Target Price | $3.73 | ★ $3.79 |
| AVG Volume (30 Days) | 1.3M | ★ 1.9M |
| Earning Date | 02-17-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $12,644,000,000.00 | N/A |
| Revenue This Year | $0.04 | N/A |
| Revenue Next Year | $0.86 | N/A |
| P/E Ratio | $1.26 | ★ N/A |
| Revenue Growth | ★ 0.74 | N/A |
| 52 Week Low | $2.24 | $1.10 |
| 52 Week High | $4.47 | $13.71 |
Technical Indicators
Market Signals| Indicator | CYH | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.88 | 42.72 |
| Support Level | $3.16 | $1.20 |
| Resistance Level | $3.25 | $1.27 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 26.23 | 42.86 |
Price Performance
Historical ComparisonAbout CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.